The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Long-Term Effect of Gene Therapy on Leber’s Congenital Amaurosis
Open accessAbstract
BACKGROUND: Mutations in RPE65 cause Leber's congenital amaurosis, a progressive retinal degenerative disease that severely impairs sight in children. Gene therapy can result in modest improvements in night vision, but knowledge of its efficacy in humans is limited. METHODS: We performed a phase 1-2 open-label trial involving 12 participants to evaluate the safety and efficacy of gene therapy with a recombinant adeno-associated virus 2/2 (rAAV2/2) vector carrying the RPE65 complementary DNA, and measured visual function over the course of 3 years. Four participants were administered a lower dose of the vector, and 8 were administered a higher dose. In a parallel study in dogs, we investigated the relationship among vector dose, visual function, and electroretinography (ERG) findings. RESULTS: Improvements in retinal sensitivity were evident, to varying extents, in six participants for up to 3 years, peaking at 6 to 12 months after treatment and then declining. No associated improvement in retinal function was detected by means of ERG. Three participants had intraocular inflammation, and two had clinically significant deterioration of visual acuity. The reduction in central retinal thickness varied among participants. In dogs, RPE65 gene therapy with the same vector at lower doses improved vision-guided behavior, but only higher doses resulted in improvements in retinal function that were detectable with the use of ERG. CONCLUSIONS: Gene therapy with rAAV2/2 RPE65 vector improved retinal sensitivity, albeit modestly and temporarily. Comparison with the results obtained in the dog model indicates that there is a species difference in the amount of RPE65 required to drive the visual cycle and that the demand for RPE65 in affected persons was not met to the extent required for a durable, robust effect. (Funded by the National Institute for Health Research and others; ClinicalTrials.gov number, NCT00643747.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“ocular AAV therapies leading to a permanent reduction in visual acuity following intraocular inflammation (9–11)”
From Engineering adeno-associated viral vectors to evade innate immune and inflammatory responses (2021) · cites this paper as [9]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“AAV dose-dependent intraocular inflammation and a few instances of persistent loss of visual acuity have been independently reported in clinical trials following subretinal AAV administration despite prophylactic immunosuppression (9–11).”
From Engineering adeno-associated viral vectors to evade innate immune and inflammatory responses (2021) · cites this paper as [9]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the phase 1/2 dose-escalation trials for RPE65-associated LCA, choroideremia, and retinitis pigmentosa GTPase regulator (RPGR)-associated X-linked retinitis pigmentosa, patients receiving higher doses of AAV have presented with various signs of retinal inflammation, including vitritis, retinitis, and choroiditis,2,6,7 implicating the presence of a cell-mediated immune response.”
From Characterizing the cellular immune response to subretinal AAV gene therapy in the murine retina (2021) · cites this paper as [2]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Despite the perceived low immunogenicity of AAV and relative immune privilege of the intraocular environment,8 dose-dependent retinal inflammation, or gene therapy-associated uveitis (GTAU), has been observed in many retinal gene therapy trials, which limits the vector dose and therapeutic efficacy.”
From Characterizing the cellular immune response to subretinal AAV gene therapy in the murine retina (2021) · cites this paper as [2]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Despite a 28-day oral corticosteroid therapy started 2 days before the first IVT, a regimen similar to that provided in several other clinical studies using IVT or sub-retinal AAV-based gene therapies,41–45 70.7% of lenadogene nolparvovec-treated eyes developed some degree of intraocular inflammation versus 10.2% of placebo-treated eyes.”
From Randomized trial of bilateral gene therapy injection for m.11778G>A MT-ND4 Leber optic neuropathy (2023) · cites this paper as [45]
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This is clinically important as intraocular inflammation could lead to irreversible loss of retinal cells, deterioration of visual function and reduced durability of treatment effect associated with a costly one-off treatment.”
From Gene Therapy-Associated Uveitis (GTAU): Understanding and mitigating the adverse immune response in retinal gene therapy (2025) · cites this paper as Bainbridge et al., 2015
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The intraocular inflammation is dose-dependent and can sometimes last for months or even years following treatment, leading to irreversible retinal structural damage and reduced visual function if uncontrolled (Bainbridge et al., 2015).”
From Gene Therapy-Associated Uveitis (GTAU): Understanding and mitigating the adverse immune response in retinal gene therapy (2025) · cites this paper as Bainbridge et al., 2015
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The intraocular inflammation is dose-dependent and can sometimes last for months or even years following treatment, leading to irreversible retinal structural damage and reduced visual function if uncontrolled (Bainbridge et al., 2015).”
From Gene Therapy-Associated Uveitis (GTAU): Understanding and mitigating the adverse immune response in retinal gene therapy (2025) · cites this paper as Bainbridge et al., 2015
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Notably, one participant developed anterior uveitis at 2 weeks, followed by CRA and reduced visual acuity by 6 months.”
From Gene Therapy-Associated Uveitis (GTAU): Understanding and mitigating the adverse immune response in retinal gene therapy (2025) · cites this paper as Bainbridge et al., 2015
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Two participants developed optic disc swelling, retinal vascular tortuosity/sheathing and mild vitritis.”
From Gene Therapy-Associated Uveitis (GTAU): Understanding and mitigating the adverse immune response in retinal gene therapy (2025) · cites this paper as Bainbridge et al., 2015
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Three out of eight participants who received the higher dose of vector (1 × 10 12 vg/eye) but none in the lower dose cohort (1 × 10 11 vg/eye) developed intraocular inflammation despite prophylactic peri-operative immunosuppression.”
From Gene Therapy-Associated Uveitis (GTAU): Understanding and mitigating the adverse immune response in retinal gene therapy (2025) · cites this paper as Bainbridge et al., 2015
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Consequently, GTAU is often diagnosed shortly after the withdrawal of systemic immunosuppression prophy laxis (Dimopoulos et al., 2018) or when the dose reaches around 15 -20 mg for slower tapers, and sometimes several weeks to months after vector administration (Bainbridge et al., 2015).”
From Gene Therapy-Associated Uveitis (GTAU): Understanding and mitigating the adverse immune response in retinal gene therapy (2025) · cites this paper as Bainbridge et al., 2015
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Although adeno-associated viral (AAV) vector-mediated retinal gene therapies have demonstrated efficacy”
From Characterizing the cellular immune response to subretinal AAV gene therapy in the murine retina (2021) · cites this paper as [2]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“The intraocular inflammation is dose-dependent and can sometimes last for months or even years following treatment, leading to irreversible retinal structural damage and reduced visual function if uncontrolled (Bainbridge et al., 2015).”
From Gene Therapy-Associated Uveitis (GTAU): Understanding and mitigating the adverse immune response in retinal gene therapy (2025) · cites this paper as Bainbridge et al., 2015
Experimental — accuracy not yet measuredIn the citing paper
“In phase I/II clinical trials for RPE65-LCA at University College London (ClinicalTrials.gov: NCT00643747), ocular inflammation was noted following SRI of 1 × 1012 vg of AAV2-RPE65.71,99”
From Current clinical applications of in vivo gene therapy with AAVs (2021) · cites this paper as [99]
In the citing paper
“subfoveal viral gene therapy has been associated with various adverse effects, such as RPE alterations, retinal thinning, foveal morphological changes, vision loss, and the variable duration of clinical effects [281,294,296,297,298].”
From Bruch’s Membrane: A Key Consideration with Complement-Based Therapies for Age-Related Macular Degeneration (2023) · cites this paper as [296]
In the citing paper
“Dose-dependent immune responses have also been observed, with high doses potentially leading to persistent inflammation and clinically significant vision loss in patients receiving high-dose AAV2 vector-based subretinal RPE65 therapy [296].”
From Bruch’s Membrane: A Key Consideration with Complement-Based Therapies for Age-Related Macular Degeneration (2023) · cites this paper as [296]
In the citing paper
“However, some adverse events linked to the glucocorticoids themselves have already been described in retinal rAAV trials which point out the need for other alternatives to mitigate the inflammation [37].”
From Risk mitigation of immunogenicity: a key to personalized retinal gene therapy (2021) · cites this paper as [37]
In the citing paper
“The results showed that retinal sensitivity was improved; however, the final transgene expression in the participants from the high dose group was adversely affected by ocular inflammation or immune responses [48].”
From Immune responses to gene editing by viral and non-viral delivery vectors used in retinal gene therapy (2022) · cites this paper as [48]
In the citing paper
“Nonetheless, inflammatory reactions to gene therapy in the eye have led to permanent vision loss for some patients7–9.”
From Investigation of Cas9 Antibodies in the Human Eye (2022) · cites this paper as [7]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hartong, D. T., Berson, E. L., & Dryja, T. P. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69740-7 · Cited by 2,924
Safety and Efficacy of Gene Transfer for Leber's Congenital Amaurosis
Maguire, A. M., Simonelli, F., Pierce, E. A., Pugh, E. N., Mingozzi, F., Bennicelli, J., Banfi, S., Marshall, K. A., Testa, F., Surace, E. M., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802315 · Cited by 2,145
Effect of gene therapy on visual function in Leber’s congenital amaurosis
Bainbridge, J. W. B., Smith, A. J., Barker, S. S., Robbie, S., Henderson, R., Balaggan, K., Viswanathan, A., Holder, G. E., Stockman, A., Tyler, N., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802268 · Cited by 1,924
Self-citationStatistics Notes: Measurement error
Bland, J. M., & Altman, D. G. (1996) · BMJ · doi:10.1136/bmj.313.7059.744 · Cited by 1,084
Hauswirth, W. W., Aleman, T. S., Kaushal, S., Cideciyan, A. V., Schwartz, S. B., Wang, L., Conlon, T. J., Boye, S. L., Flotte, T. R., Byrne, B. J., et al. (2008) · Human Gene Therapy · doi:10.1089/hum.2008.107 · Cited by 954
Rpe65 is necessary for production of 11-cis-vitamin A in the retinal visual cycle
Redmond., T. M., Yu, S., Lee, E., Bok, D., Hamasaki, D., Chen, N., Goletz, P., Ma, J.-X., Crouch, R. K., & Pfeifer, K. (1998) · Nature Genetics · doi:10.1038/3813 · Cited by 929
Maguire, A. M., High, K. A., Auricchio, A., Wright, J. F., Pierce, E. A., Testa, F., Mingozzi, F., Bennicelli, J. L., Ying, G.-S., Rossi, S., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61836-5 · Cited by 865
Leber congenital amaurosis: Genes, proteins and disease mechanisms
den Hollander, A. I., Roepman, R., Koenekoop, R. K., & Cremers, F. P. M. (2008) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2008.05.003 · Cited by 811
Cideciyan, A. V., Alemán, T. S., Boye, S. L., Schwartz, S., Kaushal, S., Román, A. J., Pang, J., Sumaroka, A., Windsor, E. A. M., Wilson, J. M., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0807027105 · Cited by 674
Jacobson, S. G. (2012) · Archives of Ophthalmology · doi:10.1001/archophthalmol.2011.298 · Cited by 639
Flagged first, then by citations
Research works printed but not linked: 3
- Poehner WJ, 2000, Mol Vis, 6, 192
- Geller SF, 2001, Invest Ophthalmol Vis Sci, 42, 1363
- 10.1056/NEJMoa1412965 · DOI
Cited by
Sorted by citations
Items 501–600 of 743
Zhang, L., Wang, W., Kim, S. M., Wang, J., Zhou, B., Kong, W., Zheng, J. Q., & Lin, X. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.900416 · Cited by 7
Alternative splicing in CEP290 mutant cats results in a milder phenotype than LCACEP290 patients
Minella, A., Wiechel, K. N., & Petersen‐Jones, S. M. (2022) · Veterinary Ophthalmology · doi:10.1111/vop.13052 · Cited by 7
Self-citationSingh, J., Goodman-Vincent, E., & Santosh, P. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24109023 · Cited by 8
Gene therapy for age-related macular degeneration: potential, feasibility, and pitfalls
Berkowitz, S. T., & Finn, A. P. (2024) · Current Opinion in Ophthalmology · doi:10.1097/icu.0000000000001043 · Cited by 8
Gene Therapy for Retinal Disease: What Lies Ahead
MacLaren, R. E. (2015) · Ophthalmologica · doi:10.1159/000438872 · Cited by 7
Visual Consequences of Delivering Therapies to the Subretinal Space
Duncan, J. L. (2017) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2016.5659 · Cited by 7
Will Optogenetics Be Used To Treat Chronic Pain Patients?
Beaudry, H., Daou, I., Ribeiro‐da‐Silva, A., & Séguéla, P. (2017) · Pain Management · doi:10.2217/pmt-2016-0055 · Cited by 7
Attenuation of Inherited and Acquired Retinal Degeneration Progression with Gene-based Techniques
Cho, G. Y., Bolo, K. A., Park, K. S., Sengillo, J. D., & Tsang, S. H. (2018) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-018-0377-1 · Cited by 8
A Quantitative Chloride Channel Conductance Assay for Efficacy Testing of AAV.BEST1
Wood, S., McClements, M. E., de la Cámara, C. M.-F., Patrício, M. I., Uggenti, C., Sekaran, S., Barnard, A. R., Manson, F. D. C., & MacLaren, R. E. (2019) · Human Gene Therapy Methods · doi:10.1089/hgtb.2018.267 · Cited by 7
Mowat, F. M., Wise, E., Oh, A., Foster, M. L., & Kremers, J. (2019) · Experimental Eye Research · doi:10.1016/j.exer.2019.05.013 · Cited by 7
Self-citationAi, J., Li, J., Su, Q., Ma, H., He, R., Wei, Q., Li, H., & Gao, G. (2021) · Gene Therapy · doi:10.1038/s41434-021-00275-5 · Cited by 7
RPE65 and retinal dystrophy: Report of new and recurrent mutations
Safari, S., Zare‐Abdollahi, D., Bushehri, A., Safari, M. R., Dehghani, A., Tahmasebi, Z., Khorshid, H. R. K., & Ghadami, M. (2020) · The Journal of Gene Medicine · doi:10.1002/jgm.3154 · Cited by 7
Gene therapy 'cure' for blindness wanes
Azvolinsky, A. (2015) · Nature Biotechnology · doi:10.1038/nbt0715-678 · Cited by 7
Vendomèle, J., Chauveau, G. A., Dalkara, D., Galy, A., & Fisson, S. (2024) · Human Gene Therapy · doi:10.1089/hum.2023.191 · Cited by 6
Multiplex viral tropism assay in complex cell populations with single-cell resolution
Keng, C. T., Guo, K., Liu, Y., Shen, K., Lim, D. S., Lovatt, M., Ang, H.-P., Mehta, J. S., & Chew, W. L. (2022) · Gene Therapy · doi:10.1038/s41434-022-00360-3 · Cited by 7
Tang, M., Zhong, L., Rong, H., Li, K., Ye, M., Peng, J., & Ge, J. (2024) · Experimental Eye Research · doi:10.1016/j.exer.2024.109931 · Cited by 6
Will our cardiomyopathy patients accept gene therapy?
Doevendans, P. A., Kupatt, C., Giacca, M., & Glijnis, P. C. (2022) · Netherlands Heart Journal · doi:10.1007/s12471-022-01665-z · Cited by 6
Retinoid Synthesis Regulation by Retinal Cells in Health and Disease
Andreazzoli, M., Longoni, B., Angeloni, D., & Demontis, G. C. (2024) · Cells · doi:10.3390/cells13100871 · Cited by 7
In vivo adenine base editing ameliorates Rho-associated autosomal dominant retinitis pigmentosa
Hu, S., Chen, Y., Zhou, Y., Cao, T., Liu, S., Ding, C., Xie, D., Liang, P., Huang, L. T., Liu, H., et al. (2024) · Journal of genetics and genomics/Journal of Genetics and Genomics · doi:10.1016/j.jgg.2024.12.012 · Cited by 6
Dai, X., Jin, X., Ye, Q., Huang, H., Duo, L., Lu, C., Bao, J., & Chen, H. (2021) · Experimental Eye Research · doi:10.1016/j.exer.2021.108776 · Cited by 6
Benefits of gene therapy for both eyes
MacLaren, R. E. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30783-8 · Cited by 6
Argus® II Retinal Prosthesis System
Falabella, P., Nazari, H. K., Schor, P., Weiland, J. D., & Humayun, M. S. (2016) · Springer eBooks · doi:10.1007/978-3-319-41876-6_5 · Cited by 6
Waizel, M. D. V., Traber, G. L., Maloca, P. M., Zinkernagel, M. S., Schmidt-Erfurth, U. M., Rubin, G. S., Roska, B., Otto, T. P., Weleber, R. G., & Scholl, H. P. N. (2019) · Ophthalmic Research · doi:10.1159/000501887 · Cited by 6
Self-citationAAV-mediated human CNGB3 restores cone function in an all-cone mouse model of CNGB3 achromatopsia
Zhang, Y., Wang, S., Xu, M., Pang, J., Yuan, Z., & Zhao, C. (2020) · Journal of Biomedical Research · doi:10.7555/jbr.33.20190056 · Cited by 6
A solid start for gene therapy in Tay–Sachs disease
Yu, T. W., & Bodamer, O. A. (2022) · Nature Medicine · doi:10.1038/s41591-022-01687-5 · Cited by 6
Clinical gene therapy restores hearing: a paradigm shift
Han, S., Chen, Z., Wang, D., Jiang, L., Fan, X., Zhong, J., Cui, C., Chen, Y., lv, J., Zhang, J., et al. (2025) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2025.07.007 · Cited by 5
Canine models of inherited retinal diseases: from neglect to well-recognized translational value
Dufour, V., & Aguirre, G. D. (2024) · Mammalian Genome · doi:10.1007/s00335-024-10091-y · Cited by 5
Targeting Age-Related Neurodegenerative Diseases by AAV-Mediated Gene Therapy
Cagin, U. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-55035-6_15 · Cited by 5
Culture of Human Retinal Explants for Ex Vivo Assessment of AAV Gene Delivery
Wu, W.-H., Tso, A., Breazzano, M. P., Jenny, L. A., Levi, S. R., Tsang, S. H., & Quinn, P. M. J. (2022) · Methods in molecular biology · doi:10.1007/978-1-0716-2651-1_28 · Cited by 5
Ren, W., Duan, S., Mei, C., Xie, C., Jiang, L., & Shi, Y. (2023) · Molecules · doi:10.3390/molecules28083500 · Cited by 5
INTRAOPERATIVE BLEB BEHAVIOR IN SUBRETINAL GENE AUGMENTATION THERAPY FOR INHERITED RETINAL DISEASES
Sisk, R. A., Berger, T. A., Williams, E. R., & Riemann, C. D. (2023) · Retina · doi:10.1097/iae.0000000000003857 · Cited by 5
Gene Augmentation of CHM Using Non-Viral Episomal Vectors in Models of Choroideremia
Toualbi, L., Toms, M., Almeida, P. V., Harbottle, R. P., & Moosajee, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242015225 · Cited by 5
Amato, A., Tschetter, W. W., Everett, L. A., Bailey, S. T., Lauer, A. K., Yang, P. G., & Pennesi, M. E. (2024) · Documenta Ophthalmologica · doi:10.1007/s10633-024-09987-6 · Cited by 5
Regressive Retinal Flecks in CRX‐Mutated Early‐Onset Retinal Dystrophy
Cicinelli, M. V., Manitto, M. P., Parodi, M. B., & Bandello, F. M. (2016) · Optometry and Vision Science · doi:10.1097/opx.0000000000000944 · Cited by 5
Optogenetics: Lighting a Path from the Laboratory to the Clinic
Kim, H. K., Alexander, A., & Soltész, I. (2017) · Neuromethods · doi:10.1007/978-1-4939-7417-7_14 · Cited by 6
Harnessing the Power of Genetic Engineering for Patients With Mitochondrial Eye Diseases
Yu‐Wai‐Man, P. (2017) · Journal of Neuro-Ophthalmology · doi:10.1097/wno.0000000000000476 · Cited by 5
Traber, G. L., Waizel, M. D. V., Maloca, P. M., Schmidt-Erfurth, U. M., Rubin, G. S., Roska, B., Cordeiro, M. F., Otto, T. P., Weleber, R. G., Lesmes, L. A., et al. (2020) · Ophthalmic Research · doi:10.1159/000504892 · Cited by 5
Self-citationImproved ocular gene transfer with a Neddylation-site modified AAV-RPE65 vector in rd12 mice
Maurya, S., Mary, B., & Jayandharan, G. R. (2020) · Eye · doi:10.1038/s41433-020-0838-8 · Cited by 5
Hamada, A., Kita, Y., Murakami, K., Matsumoto, K., Sakatani, T., Sano, T., Ogawa, O., & Kobayashi, T. (2020) · Journal of Virological Methods · doi:10.1016/j.jviromet.2020.113854 · Cited by 5
The spermatogenesis-associated protein-7 (SPATA7) gene – an overview
Kannabiran, C. (2020) · Ophthalmic Genetics · doi:10.1080/13816810.2020.1807025 · Cited by 5
Wang, J., Tao, Z., Deng, H., Cui, Y., Zhirong, X., Lyu, Q., & Zhao, J. (2022) · Nanoscale · doi:10.1039/d1nr08337f · Cited by 5
Preclinical study of rAAV2-sTRAIL: pharmaceutical efficacy, biodistribution and safety in animals
Ru, Q., Li, W., Wang, X., Zhang, S., Chen, L., Zhang, Y., Ge, Y. C., Zu, Y., Liu, Y., & Zheng, D. (2017) · Cancer Gene Therapy · doi:10.1038/cgt.2017.12 · Cited by 5
Ethical considerations in gene therapy
Levin, A. V. (2016) · Ophthalmic Genetics · doi:10.3109/13816810.2015.1121501 · Cited by 5
Spotlight on Reproduction in Domestic Dogs as a Model for Human Reproduction
Wright, S. J. (2017) · doi:10.1002/9781118881286.ch11 · Cited by 5
Assessment of Immune Responses Against AAV Encoded Transgene Products
Gorovits, B., Azadeh, M., Fiscella, M., Harrison, T., Hofer, M., Janetzki, S., Jawa, V., Long, B. R., Lu, Y., Mahnke, Y. D., et al. (2026) · The AAPS Journal · doi:10.1208/s12248-025-01192-w · Cited by 4
Retinal prosthesis: a comprehensive review
Menia, N. K., & Venkatesh, P. (2025) · Expert Review of Ophthalmology · doi:10.1080/17469899.2025.2474064 · Cited by 4
Novel photoreceptor-specific promoters for gene therapy in mid- to late-stage retinal degeneration
Sudharsan, R., Murgiano, L., Ahuja, A., Sato, Y., Kwok, J., Dolgova, N., Savina, S., Sedorovitz, M., Dufour, V., Aguirre, G. K., et al. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.05.020 · Cited by 4
Adeno-associated virus neutralising antibodies in type 1 diabetes mellitus
Andrzejewski, S., Murali, A., Ramlogan‐Steel, C. A., Edwards, K. P., Efron, N., Steel, J. C., & Layton, C. J. (2019) · Gene Therapy · doi:10.1038/s41434-019-0076-5 · Cited by 4
Aftermath of the Human Genome Project: an era of struggle and discovery
HAMDOUN, Z., & Ehsan, H. (2017) · TURKISH JOURNAL OF BIOLOGY · doi:10.3906/biy-1609-77 · Cited by 5
CRISPR in the Retina: Evaluation of Future Potential
Cho, G. Y., Justus, S., Sengillo, J. D., & Tsang, S. H. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-63904-8_8 · Cited by 4
Héon, E., & Koenekoop, R. K. (2020) · Canadian Journal of Ophthalmology · doi:10.1016/j.jcjo.2020.10.019 · Cited by 4
Genes and Gene Therapy in Inherited Retinal Disease
Shughoury, A., Ciulla, T. A., Bakall, B., Pennesi, M. E., Kiss, S., & Cunningham, E. T. (2021) · International Ophthalmology Clinics · doi:10.1097/iio.0000000000000377 · Cited by 4
Associations Between Fundus Types and Clinical Manifestations in Patients with RDH12 Gene Mutations
Jin, J., Liang, L., Jin, K. L., Zhang, H.-J., Liu, R., & Shen, Y. (2022) · Brain Topography · doi:10.1007/s10548-021-00885-7 · Cited by 4
Modulating the activity of human nociceptors with a SCN10A promoter-specific viral vector tool
Mouchbahani-Constance, S., Lagard, C., Schweizer, J., Labonté, I., Georgiopoulos, M., Otis, C., Louis, M. S., Troncy, É., Sarret, P., Ribeiro‐da‐Silva, A., et al. (2023) · Neurobiology of Pain · doi:10.1016/j.ynpai.2023.100120 · Cited by 5
Suárez-Herrera, N., Riswick, I. B., Vázquez-Domínguez, I., Duijkers, L., Karjosukarso, D. W., Piccolo, D., Bauwens, M., Baere, E. B. W. D., Cheetham, M. E., Garanto, A., et al. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.01.019 · Cited by 4
Emerging Gene Manipulation Strategies for the Treatment of Monogenic Eye Disease
Burgess, F. R., Hall, H. N., & Megaw, R. D. (2022) · Asia-Pacific Journal of Ophthalmology · doi:10.1097/apo.0000000000000545 · Cited by 4
Perspectivas da terapia gênica
Costanzi-Strauss, E., & Strauss, B. E. (2015) · Revista de Medicina · doi:10.11606/issn.1679-9836.v94i4p211-222 · Cited by 5
Gene and Cell Therapy for Inherited Retinal Dystrophies
Garita‐Hernandez, M., Goureau, O., & Dalkara, D. (2016) · Wiley eBooks · doi:10.1002/9780470015902.a0026565 · Cited by 4
Therapeutic Gene Editing in Inherited Retinal DisordersPreprint
Ling, J., Jenny, L. A., Zhou, A., & Tsang, S. H. (2022) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a041292 · Cited by 4
Canine and Feline Models of Inherited Retinal DiseasesPreprint
Petersen‐Jones, S. M., & Komáromy, A. M. (2023) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a041286 · Cited by 4
Self-citationIn vivo gene therapy: A strategy for mutations, degenerations, and tumors
Wang, T., Yu, M., Liu, P., Song, Z., Li, C., Yang, J., & Liu, N. (2025) · Genes & Diseases · doi:10.1016/j.gendis.2025.101808 · Cited by 4
Circadian Clock Gene Bmal1: A Molecular Bridge from AKI to CKD
Yang, S., Ye, Z., Chen, L., Zhou, X., Li, W., & Fan, C. (2025) · Biomolecules · doi:10.3390/biom15010077 · Cited by 3
Wu, J., Jang, H., Kwak, H., Son, M., Jiang, W., Hwang, H., Jo, D. H., Kim, D., Kim, S., & Kim, J. H. (2025) · Genome biology · doi:10.1186/s13059-025-03774-5 · Cited by 3
Institutional Conflict of Interest and the Translational Pathway
McKinney, R. E. (2016) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2016.0459 · Cited by 3
Investigation of SLA4A3 as a candidate gene for human retinal disease
Downs, L. M., Webster, A. R., Moore, A. T., Michaelides, M., Ali, R. R., Hardcastle, A. J., & Mellersh, C. S. (2016) · Journal of Negative Results in BioMedicine · doi:10.1186/s12952-016-0054-z · Cited by 3
Self-citationGene Therapy: Use of Viruses as Vectors
Nance, M. E., & Duan, D. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.95711-8 · Cited by 3
Brunetti‐Pierri, N. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-817344-2.00030-7 · Cited by 4
Gene Therapy for Retinal Diseases
Gopinath, C., Sarkar, S., & Ghosh, A. (2021) · Essentials in ophthalmology/Essentials ophthalmology · doi:10.1007/978-981-15-9184-6_30 · Cited by 3
Gene therapy in PIDs, hemoglobin, ocular, neurodegenerative, and hemophilia B disorders
Odiba, A. S., Okoro, N. O., Durojaye, O. A., & Wu, Y. (2021) · Open Life Sciences · doi:10.1515/biol-2021-0033 · Cited by 3
Park, S. A., Rhodes, J., Iwabe, S., Ying, G., Pan, W., Huang, J., & Komáromy, A. M. (2022) · Experimental Eye Research · doi:10.1016/j.exer.2022.109106 · Cited by 4
FDA’s role in expediting innovation of bioelectronic implants for vision restoration
Sandrian, M. G., Ng, E., Nguyen, T., & Eydelman, M. B. (2023) · Journal of Neural Engineering · doi:10.1088/1741-2552/acd8f1 · Cited by 3
Dong, S., Zhen, F., Zou, T., Zhou, Y., Wu, J., Wang, T., & Zhang, H. (2023) · Current Medicinal Chemistry · doi:10.2174/0109298673240896231027053716 · Cited by 3
Current situation and future of gene therapy for rare diseases
Huang, G. (2023) · Theoretical and Natural Science · doi:10.54254/2753-8818/21/20230904 · Cited by 3
Chekuri, A. K., Kondabolu, K., Kirchner, E. G., Koli, S., Chagnon, M., Krasniqi, D., Stern, M. E., Bolduc, J., Romano, G., Pagani, F., et al. (2025) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2025.102788 · Cited by 3
Sharma, P., Wimalawansa, S. M., Gould, G. C., Johnson, R. M., & Excoffon, K. J. D. A. (2016) · Human Gene Therapy Methods · doi:10.1089/hgtb.2016.123 · Cited by 3
Giers, B. C., Klein, D., Mendes-Madeira, A., Isiegas, C., Lorenz, B., Haverkamp, S., & Stieger, K. (2017) · Frontiers in Neurology · doi:10.3389/fneur.2017.00059 · Cited by 4
Stockman, A., Henning, G. B., & Rider, A. T. (2020) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2020.100937 · Cited by 4
Challenges to Gene Editing Approaches in the Retina
Bonillo, M., Pfromm, J. K., & Fischer, M. D. (2022) · Klinische Monatsblätter für Augenheilkunde · doi:10.1055/a-1757-9810 · Cited by 4
Gene-Based Therapies for Leber Hereditary Optic Neuropathy. Hype or Hope?
Mackey, D. A., Kearns, L. S., & Hewitt, A. W. (2016) · Asia-Pacific Journal of Ophthalmology · doi:10.1097/apo.0000000000000220 · Cited by 3
Optogénétique et douleur chronique : une stratégie applicable chez l’humain ?
Beaudry, H., Daou, I., Ribeiro‐da‐Silva, A., & Séguéla, P. (2016) · Douleur et Analgésie · doi:10.1007/s11724-016-0477-9 · Cited by 3
Gene therapy for Leber congenital amaurosis
Kumaran, N., Smith, A. J., Michaelides, M., Ali, R. R., & Bainbridge, J. W. (2018) · Expert Review of Ophthalmology · doi:10.1080/17469899.2018.1429916 · Cited by 3
Self-citationSuccess of Gene Therapy in Late-Stage Treatment
Koch, S., & Tsang, S. H. (2018) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-75402-4_13 · Cited by 3
AAV-Mediated Gene Therapy for CRB1-Hereditary Retinopathies
Alves, C. H., & Wijnholds, J. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.79308 · Cited by 3
Dikkaya, F., Seyhan, S., Erdur, S. K., Şentürk, F., & Aras, C. (2020) · Ophthalmic Genetics · doi:10.1080/13816810.2020.1731837 · Cited by 3
Visual Impairment in Infants and Young Children
Fulton, A. B., & Yang, P. G. (2022) · Springer eBooks · doi:10.1007/978-3-030-42634-7_279 · Cited by 3
Treated PDR Reveals Age-Appropriate Vision Deterioration But Distorted Retinal Organization
Chen, X. D., Omari, A. A., Hwang, M. W., Kwark, L., Dakki, N., Farsiu, S., & Gardner, T. W. (2020) · Translational Vision Science & Technology · doi:10.1167/tvst.9.3.3 · Cited by 3
The rod synapse in aging wildtype and Dscaml1 mutant mice
Clemons, M. R., Dimico, R. H., Black, C. X., Schlussler, M. K., Camerino, M. J., Aldinger-Gibson, K., Bartle, A., Reynolds, N., Eisenbrandt, D., Rogers, A., et al. (2023) · PLoS ONE · doi:10.1371/journal.pone.0290257 · Cited by 2
Ocular genetics in the Japanese population
Hotta, Y., Torii, K., & Takayama, M. (2024) · Japanese Journal of Ophthalmology · doi:10.1007/s10384-024-01109-8 · Cited by 2
Ching, J., Arai, M., Oba, M., Miyazato, M., Kobayashi, Y., Tanaka, S., Kitahata, S., Inoue, T., Maruyama-Inoue, M., & Kadonosono, K. (2025) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-025-06960-0 · Cited by 2
WFS1 gene delivery rescues visual function in a mouse model of Wolfram syndrome
Jagodzinska, J., Péquignot, M. O., Sarzi, E., Quilès, M., Cazevieille, C., Müller, A., Kõks, S., & Delettre, C. (2026) · Acta Neuropathologica Communications · doi:10.1186/s40478-026-02295-x · Cited by 2
Duarte, F. T., & Arsenijévic, Y. (2025) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2025.101424 · Cited by 2
Zhang, Y., Chen, Q., & Lv, J. (2026) · Frontiers in Pediatrics · doi:10.3389/fped.2025.1713783 · Cited by 2
mRNA delivery to the retina restores REP1 function in choroideremia
de Lemos, L., Antas, P., Carvalho, C., Castro, M., Bruno, D., Fonseca, A. F., Rakshit, S., & Seabra, M. C. (2026) · Molecular Therapy Advances · doi:10.1016/j.omta.2026.201768 · Cited by 2
Spring Forward: ESGCT Trains the Next Generation of Gene and Cell Therapists
Woods, V. M. A., & Brimble, M. A. (2018) · Human Gene Therapy · doi:10.1089/hum.2018.29076.vmw · Cited by 2
Gentherapie in der Augenheilkunde
Priglinger, C., Gerhardt, M. J., Rudolph, G., Priglinger, S. G., & Michalakis, S. (2023) · Die Ophthalmologie · doi:10.1007/s00347-023-01883-9 · Cited by 3
Clinical and Ocular Inflammatory Inhibitors of Viral-Based Gene Therapy of the Retina
Ohlhausen, M. E., & Conrady, C. D. (2024) · Acta Microbiologica Hellenica · doi:10.3390/amh69030018 · Cited by 2
Schlemm's canal-selective Tie2/TEK knockdown induces sustained ocular hypertension in adult mice
Schwakopf, J., Romero, C. O., López, N. N., Millar, J. C., Vetter, M. L., & Bosco, A. (2024) · Experimental Eye Research · doi:10.1016/j.exer.2024.110114 · Cited by 3
Emerging Gene Therapy Treatments for Inherited Retinal Diseases
Bakall, B., Klein, K. A., & Hariprasad, S. M. (2018) · Ophthalmic surgery, lasers & imaging retina · doi:10.3928/23258160-20180628-02 · Cited by 2
Inherited retinal dystrophy: first results of RPE65 gene replacement therapy in Russia
Кадышев, В. В., Zolnikova, I. V., Khalanskaya, O. V., Stepanova, A. A., & Kutsev, S. I. (2022) · Russian Annals of Ophthalmology · doi:10.17116/oftalma202213804148 · Cited by 2
New Frontiers of Retinal Therapeutic Innovation & Strategic Insights
Qiu, T. G., & Laties, A. M. (2015) · Cited by 2
Metadata
- Authors
- Bainbridge, J. W. B., Mehat, M. S., Sundaram, V., Robbie, S. J., Barker, S. E., Ripamonti, C., Georgiadis, A., Mowat, F. M., Beattie, S. G., Gardner, P. J., Feathers, K. L., Luong, V. A., Yzer, S., Balaggan, K., Viswanathan, A., de Ravel, T. J. L., Casteels, I., Holder, G. E., Tyler, N., Fitzke, F. W., Weleber, R. G., Nardini, M., Moore, A. T., Thompson, D. A., Petersen-Jones, S. M., Michaelides, M., van den Born, L. I., Stockman, A., Smith, A. J., Rubin, G., & Ali, R. R.
- Affiliations
- Moorfields Eye Hospital (GB)
- Michigan State University (US)
- University of Michigan (US)
- Rotterdam Eye Hospital (NL)
- Universitair Ziekenhuis Leuven (BE)
- Oregon Health & Science University (US)
- ORCID
- Bainbridge, James W.B.
- Sundaram, Venki
- Robbie, Scott J.
- Georgiadis, Anastasios
- Mowat, Freya M.
- Beattie, Stuart G.
- Yzer, Suzanne
- Balaggan, Kamaljit
- Viswanathan, Ananth
- Casteels, Ingele
- Holder, Graham E.
- Tyler, Nick
- Weleber, Richard G.
- Moore, Anthony T.
- Thompson, Debra A.
- Michaelides, Michel
- Smith, Alexander J.
- Rubin, Gary
- Ali, Robin R.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-05-14
- Volume
- 372
- Issue
- 20
- Pages
- 1887-1897
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC4497809
- OpenAlex
- W265142245
- Semantic Scholar
- 31832b3aa3500171fc5f2a951f0a4124bd40068d
- Cited by
- 743
- References
- 29
- Citations by year
- 2026: 36 · 2025: 36 · 2024: 46 · 2023: 44 · 2022: 63 · 2021: 92 · 2020: 81 · 2019: 68 · 2018: 79 · 2017: 97 · 2016: 72 · 2015: 27
- FWCI
- 39.82
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Durham Research Online (Durham University) (acceptedVersion)
- Durham Research Online (Durham University) (submittedVersion, cc-by)
- Lirias (KU Leuven) (submittedVersion, other-oa)
- UCL Discovery (University College London) (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Research Portal (King's College London) (submittedVersion, other-oa)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- Funders
- Research to Prevent Blindness
- Wellcome Trust
- Massachusetts Medical Society
- National Institute for Health and Care Research (NF-SI-0507-10204, NF-SI-0513-10074, NIHR-RP-011-003)
- Sir Jules Thorn Charitable Trust
- University College London
- European Commission
- Ulverscroft Foundation
- Durham University
- KU Leuven
- Moorfields Eye Hospital NHS Foundation Trust
- Directorate for Biological Sciences
- Medical Research Council (MR/K024000/1, MR/M015815/1, MR/J005215/1)
- Engineering and Physical Sciences Research Council (EP/J017698/1, EP/J005193/1)
- Biotechnology and Biological Sciences Research Council (BB/M00211X/1)
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Keywords
- Leber congenital amaurosis, RPE65, gene therapy, retinal degeneration, visual function, retinal sensitivity, electroretinogram, vector dose, intraocular inflammation, visual acuity, canine model, species differences, long-term efficacy and safety
- MeSH terms
- Retinoid Isomerohydrolase, Dependovirus, Adolescent, Animals, Child, Disease Models, Animal, Dogs, Genetic Vectors, Humans, Mutation, Retina, Vision, Ocular, Genetic Therapy, DNA, Complementary, Disease Progression, cis-trans-Isomerases, Photoreceptor Cells, Vertebrate, Young Adult, Leber Congenital Amaurosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
